Omnicell Inc
$ 36.37
-0.76%
23 Apr - close price
- Market Cap 1,654,009,000 USD
- Current Price $ 36.37
- High / Low $ 37.01 / 35.84
- Stock P/E 909.25
- Book Value 27.36
- EPS 0.04
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE N/A %
- 52 Week High 55.00
- 52 Week Low 22.66
About
Omnicell, Inc., provides medication management automation solutions and adherence tools for health care systems and pharmacies in the United States and internationally. The company is headquartered in Mountain View, California.
Analyst Target Price
$57.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-23 | 2026-02-05 | 2025-10-29 | 2025-07-31 | 2025-05-06 | 2025-02-06 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-08 | 2023-11-02 | 2023-08-01 |
| Reported EPS | 0 | 0.4 | 0.51 | 0.45 | 0.26 | 0.6 | 0.56 | 0.51 | 0.03 | 0.33 | 0.62 | 0.57 |
| Estimated EPS | 0.2729 | 0.4963 | 0.36 | 0.27 | 0.2 | 0.58 | 0.42 | 0.14 | -0.09 | 0.15 | 0.47 | 0.28 |
| Surprise | -0.2729 | -0.0963 | 0.15 | 0.18 | 0.06 | 0.02 | 0.14 | 0.37 | 0.12 | 0.18 | 0.15 | 0.29 |
| Surprise Percentage | -100% | -19.4036% | 41.6667% | 66.6667% | 30% | 3.4483% | 33.3333% | 264.2857% | 133.3333% | 120% | 31.9149% | 103.5714% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMCL
2026-04-23 01:39:22
Omnicell (NASDAQ: OMCL) is scheduled to announce its financial results before the market opens on April 28. Analysts anticipate the company will report earnings per share (EPS) of $0.09 and revenue of $293.08 million for the upcoming quarter. This release will provide insight into the company's recent operational performance.
2026-04-21 11:08:45
The global Pharmacy Automation Systems Market is projected to reach USD 12.05 billion by 2033, growing at a CAGR of 7.0% from USD 7.44 billion in 2025. This growth is driven by the increasing need for accuracy, efficiency, and safety in pharmaceutical dispensing, reduction of medication errors, and advancements in robotics and AI. North America leads the market with over 40% share, supported by its advanced healthcare infrastructure and focus on reducing operational costs.
2026-04-20 15:38:52
Hims & Hers Health has seen a significant surge, driven partly by a potential FDA decision on compounding pharmacies and strong fourth-quarter results, while Omnicell's performance lagged. The article highlights the differing fortunes of healthcare technology companies, with Hims & Hers and Privia Health showing a more positive outlook compared to Omnicell. Hims & Hers' stock jumped ahead of its May 11 earnings release, fueled by investor optimism about its expansion into peptides and robust subscriber growth.
2026-04-20 11:38:52
The global medical cart market is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 14.2% from USD 3.90 billion in 2025. This growth is driven by increasing demand for efficient healthcare infrastructure, rising adoption of digital healthcare technologies, and the expansion of healthcare facilities. North America currently leads the market with a 40% share, fueled by advanced healthcare infrastructure and digital system adoption.
2026-04-18 21:38:52
Omnicell, Inc., a small-cap company in the Computers - Software & Consulting sector, has seen a slight stock price increase to $37.60, with a 21.49% return over the past year, though it underperformed the S&P 500. The stock shows mixed technical indicators and notable volatility, including a 17.00% decline year-to-date. The article provides details on technical signals and performance metrics while highlighting the company's 52-week high and low.
2026-04-18 06:38:59
Omnicell, Inc. (NASDAQ:OMCL) has received an average "Moderate Buy" recommendation from eight brokerages, with an average 12-month price target of $58.50. Despite missing quarterly EPS estimates, the company's revenue was in line with expectations, and institutional investors have significantly increased their holdings. Insider trading activity included an EVP selling 7,405 shares, reducing his stake by 7.11%.
